Cenra Inc. (TPE:3716)
34.00
-0.75 (-2.16%)
At close: Aug 18, 2026
Cenra Revenue
Cenra had revenue of 2.23B TWD in the quarter ending March 31, 2026, a decrease of -1.19%. This brings the company's revenue in the last twelve months to 8.54B, down -3.90% year-over-year. In the year 2025, Cenra had annual revenue of 8.57B, down -3.91%.
Revenue (ttm)
8.54B
Revenue Growth
-3.90%
P/S Ratio
0.58
Revenue / Employee
15.76M
Employees
542
Market Cap
4.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.57B | -348.78M | -3.91% |
| Dec 31, 2024 | 8.92B | 344.17M | 4.01% |
| Dec 31, 2023 | 8.57B | 118.21M | 1.40% |
| Dec 31, 2022 | 8.46B | 507.51M | 6.38% |
| Dec 31, 2021 | 7.95B | -232.06M | -2.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| CHC Healthcare Group | 4.65B |
| Panion & Bf Biotech | 2.11B |
| Orient Pharma | 1.52B |
| Mycenax Biotech | 815.34M |
| Ever Fortune.AI | 376.20M |
| Caliway Biopharmaceuticals | 29.39M |
| Pell Bio-Med Technology | 28.93M |